Epigallocatechin gallate

Generic Name: Epigallocatechin gallate

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₈O_₁₁

CAS Number: 989-51-5

Unique Ingredient Identifier: BQM438CTEL

Background: Epigallocatechin gallate has been investigated for the treatment of Hypertension and Diabetic Nephropathy.

Clinical Trials

Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia

Phase 2

Completed

Conditions: Pneumonia, Interstitial
Cancer Patients

Interventions: Drug: EGCG

First Posted Date: 2025-04-11

Last Posted Date: 2025-04-11

Lead Sponsor: Shandong Cancer Hospital and Institute

Target Recruit Count: 111

Registration Number: NCT06924749

Locations: 🇨🇳
Shan Dong cancer hospital and institute, Jinan, Shandong, China
🇨🇳
Hanxi Zhao, Jinan, Shandong, China

EGCG for the Prevention and Treatment of TIPN

Phase 1

Recruiting

Conditions: Chemotherapy-induced Peripheral Neuropathy

Interventions: Drug: Alcohol
Drug: Epigallocatechin-3-Gallate

First Posted Date: 2024-07-29

Last Posted Date: 2024-07-29

Lead Sponsor: Han Xi Zhao

Target Recruit Count: 36

Registration Number: NCT06524609

Locations: 🇨🇳
Shandong First Medical University Affiliated Cancer Hospital (Shandong Academy of Medical Sciences), Jinan, Shandong, China

Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect

Phase 1

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: EGCG 300 mg
Drug: Placebo for EGCG 300 mg
Drug: EGCG 600 mg
Drug: Placebo for EGCG 600 mg

First Posted Date: 2024-02-20

Last Posted Date: 2024-11-18

Lead Sponsor: Hal Chapman

Target Recruit Count: 22

Registration Number: NCT06265532

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Reducing Frailty for Older Cancer Survivors Using Supplements II

Phase 2

Recruiting

Conditions: Inflammation
Frailty

Interventions: Drug: Epigallocatechin-3-Gallate (EGCG)
Drug: Microcrystalline cellulose (MCC)
Dietary Supplement: Ascorbic Acid (Vitamin C)

First Posted Date: 2023-10-05

Last Posted Date: 2025-01-29

Lead Sponsor: University of Rochester

Target Recruit Count: 118

Registration Number: NCT06068543

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States

Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients

Phase 1

Recruiting

Conditions: Interstitial Pneumonia
Neoplasms Malignant

Interventions: Drug: EGCG

First Posted Date: 2023-03-07

Last Posted Date: 2023-05-30

Lead Sponsor: Shandong Cancer Hospital and Institute

Target Recruit Count: 78

Registration Number: NCT05758571

Locations: 🇨🇳
Shandong Cancer Hospital, Jinan, Shandong, China

Reducing Frailty for Older Cancer Survivors Using Supplements

Phase 2

Completed

Conditions: Frailty
Inflammation

Interventions: Drug: Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)

First Posted Date: 2020-09-17

Last Posted Date: 2023-09-21

Lead Sponsor: University of Rochester

Target Recruit Count: 14

Registration Number: NCT04553666

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

Phase 2

Active, not recruiting

Conditions: Prostate Cancer
Prostate Adenocarcinoma

Interventions: Drug: Placebo
Drug: Sunphenon

First Posted Date: 2020-03-09

Last Posted Date: 2025-03-11

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 115

Registration Number: NCT04300855

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States

Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

Early Phase 1

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Epigallocatechin-3-gallate (EGCG)

First Posted Date: 2019-04-26

Last Posted Date: 2022-12-22

Lead Sponsor: Hal Chapman

Target Recruit Count: 35

Registration Number: NCT03928847

Locations: 🇺🇸
UC San Francisco, San Francisco, California, United States

Green Tea Extract for Endometriosis Treatment

Phase 2

Completed

Conditions: Endometriosis

Interventions: Drug: SUNPHENON EGCg
Drug: Placebo

First Posted Date: 2016-07-14

Last Posted Date: 2023-02-08

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 185

Registration Number: NCT02832271

Locations: 🇭🇰
Prince of Wales Hospital, Shatin, Hong Kong

Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy

Phase 2

Conditions: Dermatitis
Prevention & Control
Epigallocatechin Gallate
Breast Neoplasms

Interventions: Drug: placebo
Drug: EGCG

First Posted Date: 2015-10-20

Last Posted Date: 2019-04-05

Lead Sponsor: Shandong Cancer Hospital and Institute

Target Recruit Count: 68

Registration Number: NCT02580279

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy